Literature DB >> 35355838

Nonselective Beta-Blockers in Portal Hypertension: Why, When, and How?

Anahita Rabiee1, Guadalupe Garcia-Tsao1,2, Elliot B Tapper3,4.   

Abstract

Content available: Author Interview and Audio Recording.
© 2021 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2022        PMID： 35355838      PMCID： PMC8958249          DOI： 10.1002/cld.1182

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  18 in total

1.  Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.

Authors:  Guadalupe Garcia-Tsao; Juan G Abraldes; Annalisa Berzigotti; Jaime Bosch
Journal:  Hepatology       Date:  2016-12-01       Impact factor: 17.425

2.  Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.

Authors:  Luis Téllez; Luis Ibáñez-Samaniego; Candelas Pérez Del Villar; Raquel Yotti; Javier Martínez; Laura Carrión; Enrique Rodríguez de Santiago; Maite Rivera; Ana González-Mansilla; Óscar Pastor; Javier Bermejo; Rafael Bañares; Agustín Albillos
Journal:  J Hepatol       Date:  2020-05-21       Impact factor: 25.083

3.  Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.

Authors:  Càndid Villanueva; Agustín Albillos; Joan Genescà; Juan G Abraldes; Jose L Calleja; Carles Aracil; Rafael Bañares; Rosa Morillas; María Poca; Beatriz Peñas; Salvador Augustin; Joan Carles Garcia-Pagan; Oana Pavel; Jaume Bosch
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

Review 4.  Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults.

Authors:  Lise Lotte Gluud; Aleksander Krag
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

5.  Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.

Authors:  Juan G Abraldes; Ilaria Tarantino; Juan Turnes; Juan Carlos Garcia-Pagan; Juan Rodés; Jaime Bosch
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

6.  Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis.

Authors:  Tammo L Tergast; Markus Kimmann; Hans Laser; Svetlana Gerbel; Michael P Manns; Markus Cornberg; Benjamin Maasoumy
Journal:  Aliment Pharmacol Ther       Date:  2019-08-02       Impact factor: 8.171

7.  Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.

Authors:  Càndid Villanueva; Carles Aracil; Alan Colomo; Virginia Hernández-Gea; Josep M López-Balaguer; Cristina Alvarez-Urturi; Xavier Torras; Joaquim Balanzó; Carlos Guarner
Journal:  Gastroenterology       Date:  2009-04-01       Impact factor: 22.682

8.  Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.

Authors:  Laura Turco; Guadalupe Garcia-Tsao; Ilenia Magnani; Marcello Bianchini; Martina Costetti; Cristian Caporali; Stefano Colopi; Emilio Simonini; Nicola De Maria; Federico Banchelli; Rosario Rossi; Erica Villa; Filippo Schepis
Journal:  J Hepatol       Date:  2018-01-10       Impact factor: 25.083

9.  Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.

Authors:  Thomas Reiberger; Arnulf Ferlitsch; Berit A Payer; Mattias Mandorfer; Birgit B Heinisch; Hubert Hayden; Frank Lammert; Michael Trauner; Markus Peck-Radosavljevic; Harald Vogelsang
Journal:  J Hepatol       Date:  2012-12-20       Impact factor: 25.083

10.  Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.

Authors:  Granville J Matheson; Juan G Abraldes; Wayne Bai; Mustafa Al-Karaghouli; Jesse Stach; Shuen Sung
Journal:  Hepatology       Date:  2021-08-15       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.